Last reviewed · How we verify
Mepolizumab 300 mg
Mepolizumab 300 mg, marketed by Azienda Ospedaliero Universitaria di Cagliari, is a biologic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence, supported by robust clinical trial results. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Mepolizumab 300 mg |
|---|---|
| Also known as | Nucala |
| Sponsor | Azienda Ospedaliero Universitaria di Cagliari |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA (PHASE4)
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents (PHASE2)
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) (PHASE3)
- Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps (PHASE4)
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE4)
- Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 (PHASE3)
- Effect of Mepolizumab on Severe Eosinophilic Asthma
- Mepo for Eosinophilic Esophagitis (EoE) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab 300 mg CI brief — competitive landscape report
- Mepolizumab 300 mg updates RSS · CI watch RSS
- Azienda Ospedaliero Universitaria di Cagliari portfolio CI